Billionaire Ken Griffin's hedge fund Citadel has taken a short position in British drugmaker GSK , the Financial Times ...

The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...

NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws ...

Q4 2024 dividend of 16p declared; 61p FY 2024; 64p expected for 2025. GSK (GSK) now intends to commence a GBP 2B share buyback programme, to be implemented over the next 18 months. Published first ...

GSK shares added ~6% in London trading on Wednesday after the British drugmaker lifted its 2031 outlook and announced a new share buyback program alongside better-than-expected earnings for Q4 2025.

The company plans five new product approvals in 2025, including Blenrep for multiple myeloma and depemokimab for severe asthma. Specialty medicines accounted for more than 80% of GSK's growth in ...

If approved, the new presentation will offer a convenient administration option to healthcare professionals Globally, up to 1 in 3 adults will develop shingles in their lifetime 1,2,3,4 Over 25 ...

and GSK has to prove its drug development pipeline is packed with new blockbuster treatments. “An increased dividend and the launch of a first major share buyback in more than a decade suggest ...

GSK said it expects core operating profits to rise by between 6% and 8% this year, with turnover set to lift by between 3% and 5%. It added that it expects further growth to be boosted by its strong ...

Biopharmaceutical company GSK is growing its Massachusetts work force, announcing plans to move its vaccines research and development and infectious disease teams from suburban Maryland to ...

still linger, and GSK has to prove its drug development pipeline is packed with new blockbuster treatments.

Pharmaceuticals giant GlaxoSmithKline has increased its long-term sales guidance amid hopes for a boost from new speciality medicines (Andy Buchanan/PA) Pharmaceuticals giant GlaxoSmithKline (GSK ...